Skip to content

A study for evaluating the safety of the intake of a test food.

A study for evaluating the safety of the intake of a test food. - A study for evaluating the safety of the intake of a test food.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000045361
Enrollment
48
Registered
2022-12-21
Start date
2021-09-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

Take one bag of the test food once a day for 4 weeks. Take one bag of the placebo once a day for 4 weeks.

Sponsors

EP Mediate Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Men and women between 20 and 64 years of age. (2) Healthy persons who defecated 6 or more times per week during the previous observation period and had diarrhea or soft stools (Bristol stool scale 6 or 7) less than once per week (24 persons) (3) Persons prone to constipation who defecated 3-5 times a week in the previous observation period and had diarrhea or soft stools (Bristol stool scale 6 and 7) less than once a week (12 persons) (4) Those who defecated more than 3 times a week and had diarrhea or soft stool (Bristol stool scale 6 or 7) more than once a week in the previous observation period (12 persons)

Exclusion criteria

Exclusion criteria: (1) Those who regularly use foods (including foods for specified health uses) that contain a lot of dietary fiber materials (indigestible dextrin, polydextrose, indigestible glucan, etc.) (2) Those who regularly use medicines, health foods, foods for specified health uses, or functional foods that may affect bowel movements. (3) Those who are in the habit of consuming a large amount of foods that are thought to affect bowel movements (foods rich in dietary fiber and lactic acid bacteria) (4) Persons who are visiting a hospital and using medication for a bowel movement-related disease or who are regularly using over-the-counter laxatives at the time of research participation. (5) Those with a history or current condition of drug or alcohol dependence. (6) Persons with serious diseases such as diabetes, liver disease, renal disease, cardiac disease, or those with pre-existing diseases. (7) Persons at risk of developing allergies related to the research. (8) Those with a disease under treatment or with a history of serious disease that required medication. (9) Persons whose anthropometric, physical, and clinical values are significantly out of the reference range before the start of intake. (10) Those who have participated in other clinical research within one month prior to obtaining consent to participate in this study, or those who plan to participate in other clinical research after obtaining consent to participate in this. (11) Those who are pregnant or plan to become pregnant or breastfeed during the study period. (12) Those who are judged to be unsuitable as subjects based on the answers to the lifestyle questionnaire. (13) Any other person who is judged as inappropriate as a subject by the Chief Medical Officer.

Design outcomes

Primary

MeasureTime frame
Hematologic test Blood biochemistry test Urine analysis Blood pressure/pulsation Weight/body mass index Bowel movement status (frequency of bowel movements, number of days of bowel movements, volume of bowel movements, stool characteristics) Adverse event Evaluate at points of 2 week and 4 week of intake and 2 weeks after the end of ingestion period

Countries

Japan

Contacts

Public ContactShingo Yamamichi

EP Mediate Co., Ltd. Development Business Headquarters, TTC Center, Trial Planning Department

yamamichi.shingo578@eps.co.jp090-4821-1099

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026